Tumor necrosis factor inhibitor therapy for rheumatoid arthritis

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 709-715

  Naguwa, Stanley M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic response modifiers; Corticosteroids; Disease modifying antirheumatic drugs; DMARDs; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; IMMUNOPATHOLOGY; INFECTION; PATHOPHYSIOLOGY; REMISSION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TUMOR;

EID: 25444482353     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.115     Document Type: Conference Paper

References (43)

1. CHOY, E.H. & G.S. PANAYI. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344: 907-916.
2. SMITH, J.B. & M.K. HAYNES. 2002. Rheumatoid arthritis - a molecular understanding. Ann. Intern. Med. 136: 908-922.
3. HATA, H., N. SAKAGUCHI, H. YOSHITOMI, et al. 2004. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. 114: 582-588.
4. OLSEN, N.J. & C.M. STEIN. 2004. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350: 2167-2179.
5. EDWARDS, J.C., L. SZCZEPANSKI, J. SZECHINSKI, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581.
6. BRENNAN, F.M., K.A. BROWNE, P.A. GREEN, et al. 1997. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br. J. Rheumatol. 36: 643-650.
7. CHARLES, P., M.J. ELLIOTT, D. DAVIS, et al. 1999. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163: 1521-1528.
8. BORCHERS, A.T., C.L. KEEN, G.S. CHEEMA & M.E. GERSHWIN. 2004. The use of methotrexate in rheumatoid arthritis. Semin. Arthritis Rheum. 34: 465-483.
9. O'DELL, J.R., C.E. HAIRE, N. ERIKSON, et al. 1996. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334: 1287-1291.
10. WEINBLATT, M.E., J.M. KREMER, A.D. BANKHURST, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor recepton:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340: 253-259.
11. MAINI, R., E.W. ST. CLAIR, F. BREEDVELD, et al. 1999. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939.
12. WEINBLATT, M.E., E.C. KEYSTONE, D.E. FURST, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48: 35-45.
13. BATHON, J.M., R.W. MARTIN, R.M. FLEISCHMANN, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343: 1586-1593.
14. QUINN, M.A., P.G. CONAGHAN, P.J. O'CONNOR, et al. 2005. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52: 27-35.
15. WEINBLATT, M.E., et al. 2004. Efficacy and safety of over 7 years of etanercept therapy in North American patients with early and long standing rheumatoid arthritis. Arthritis Rheum. 50: 5184.
16. MAINI, R.N., F.C. BREEDVELD, J.R. KALDEN, et al. 2004. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50: 1051-1065.
17. SCHIFF, M.H. et al. 2004. Significant clinical improvement at 6 months are sustained over 4 years in patients with rheumatoid arthritis treated with adalimumab plus methotrexate. Arthritis Rheum. 50: 5182.
18. FRANSEN, J., M.C. CREEMERS & P.L. VAN RIEL. 2004. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43: 1252-1255.
19. KLARESKOG, L., D. VAN DER HEIJDE, J.P. DE JAGER, et al. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-681.
20. LIPSKY, P.E., D.M. VAN DER HEIJDE, E.W. ST. CLAIR, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343: 1594-1602.
21. KEYSTONE, E.C., A.F. KAVANAUGH, J.T. SHARP, et al. 2004. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50: 1400-1411.
22. HOVING, J.L., R. BUCHBINDER, S. HALL, et al. 2004. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J. Rheumatol. 31: 663-675.
23. GHOZLAN, R. & H. VACHER. 2000. Where is imaging going in rheumatology? Bailliere's Best Pract. Res. Clin. Rheumatol. 14: 617-633.
24. DORAN, M.F., C.S. CROWSON, G.R. POND, et al. 2002. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 46: 2287-2293.
25. WOLFE, F. & K. MICHAUD. 2004. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 50: 1740-1751.
26. HAMILTON, C.D. 2003. Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum. 48: 2085-2091.
27. MEDINA, F., V. RIVERA, J. FUENTES, et al. 2004. Is there a role for PPD and chest radiography in identification of asymptomatic tuberculosis in rheumatic diseases? Arthritis Rheum. 50: 5126.
28. IMPERATO, A.K., S. SMILES & S.B. ABRAMSON. 2004. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr. Opin. Rheumatol. 16: 199-205.
29. CALABRESE, L.H., N. ZEIN & D. VASSILOPOULOS. 2004. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. 63 (Suppl. 2): ii18-ii24.
30. ERIKSSON, C., S. ENGSTRAND, K.G. SUNDQVIST & S. RANTAPAA-DAHLQVIST. 2004. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha. Ann. Rheum. Dis. 64: 403-407.
31. HYRICH, K.L., A.J. SILMAN, K.D. WATSON & D.P. SYMMONS. 2004. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. 63: 1538-1543.
32. MOHAN, N., E.T. EDWARDS, T.R. CUPPS, et al. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44: 2862-2869.
33. JOIS, R., M. SOMERVILLE, A. BROOKSBY, et al. 2004. Biologics in clinical practice-better than expected? EULAR 2004 abstr. online FRI 0067.
34. BLUMENAUER, B., M. JUDD, A. CRANNEY, et al. 2003. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 4: CD004525.
35. BLUMENAUER, B., M. JUDD, G. WELLS, et al. 2002. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 3: CD003785.
36. CRISWELL, L.A., R.F. LUM, K.N. TURNER, et al. 2004. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50: 2750-2756.
37. SCHOTTE, H., B. SCHLUTER, S. DRYNDA, et al. 2004. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64: 575-581.
38. DRYNDA, S., B. RINGEL, M. KEKOW, et al. 2004. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy. Pathol. Res. Pract. 280:165-171.
39. FURST, D.E., F.C. BREEDVELD, J.R. KALDEN, et al. 2002. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann. Rheum. Dis. 61 (Suppl. 2): ii2-ii7.
40. YOCUM, D. 2004. Effective use of TNF antagonists. Arthritis Res. Ther. 6 (Suppl. 2): S24-S30.
41. HARAOUI, B., E.C. KEYSTONE, J.C. THORNE, et al. 2004. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J. Rheumatol. 31: 2356-2359.
42. VAN DER BIJL, A.E., F.C. BREEDVELD, C. ANTONI, et al. 2004. Infliximab failures in rheumatoid arthritis can be successfully treated with adalimumab. EULAR 2004 abstr. online FRI 0055.
43. HANSEN, K.E., J.P. HILDEBRAND, M.C. GENOVESE, et al. 2004. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 31: 1098-1102.